The restoration of coronary blood flow in acute myocardial infarction

Journal of Interventional Cardiology

Volumn 11, Issue 5 II, 1998, Pages

  Timmis, Gerald C ^a   Timmis, Steven B H ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; FIBRINOGEN RECEPTOR ANTAGONIST; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ACUTE HEART INFARCTION; CONFERENCE PAPER; CORONARY ARTERY BLOOD FLOW; DRUG EFFICACY; FIBRINOLYTIC THERAPY; HEART CATHETERIZATION; HEART MUSCLE REPERFUSION; HEART MUSCLE REVASCULARIZATION; HUMAN; PRIORITY JOURNAL; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT PLANNING;

EID: 0031773113     PISSN: 08964327     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8183.1998.tb00183.x     Document Type: Conference Paper

References (68)

1. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;II:349-360.
2. GISSI (Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto miocardico). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986:I:397-401.
3. AIMS (APSAC Intervention Mortality Study) Trial Study Group. Effects of intravenous APSAC on mortality after acute myocardial infarction: Preliminary report of a placebo-controlled clinical trial. Lancet 1988;I:545-549.
4. Cannon CP, Braunwald E, McCabe CH, et al. The Thrombolysis In Myocardial Infarction (TIMI) Trials: The first decade. J Interven Cardiol 1995;8:117-135.
5. Califf RM, White HD, Van de Werf F, et al. One-year results from the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) Investigators. Circulation 1996;94:1233-1238.
6. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indication for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994;343:311-322.
7. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: A randomised trail of Streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41, 299 cases of suspected acute myocardial infarction. Lancet 1992;339:753-770.
8. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;I:397-401.
9. Boersma E, Maas ACP, Deckers JW, et al. Early thrombolytic treatment in acute myocardial infarction: Reappraisal of the golden hour. Lancet 1996:348:771-775.
10. McNeill AJ, Cunningham SR, Flannery DJ, et al. A double blind placebo controlled study of early and late administration of recombinant tissue plasminogen activator in acute myocardial infarction. Br Heart J 1989;61:316-321.
11. Schofer J, Büttner J, Geng G, et al. Prehospital thrombolysis in acute myocardial infarction. Am J Cardiol 1990;66:1429-1433.
12. Barbash GI, Roth A, Hod H, et al. Improved survival but not left ventricular function with early and prehospital treatment with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol 1990;66:261-266.
13. McAleer B, Ruane B, Burke E, et al. Prehospital thrombolysis in a rural community: Short-and long-term survival. Cardiovasc Drugs Ther 1992;6:369-372.
14. The GREAT Group. Feasibility, safety, and efficacy of domiciliary thrombolysis by general practitioners: Grampian Region Early Anistreplase Trial. Br Med J 1992;305:548-553.
15. The European Myocardial Infarction Project Group. Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction. N Engl J Med 1993;329:383-389.
16. Weaver WD, Cerqueira M, Hallstrom AP, et al. Prehospital-initiated vs hospital-initiated thrombolytic therapy. JAMA 1993;270:1211-1216.
17. EMERAS (Estudio Multicéntrico Estreptoquinasa Repúblicas de América del Sur) Collaborative Group. Randomised trial of late thrombolysis in patients with suspected acute myocardial infarction. Lancet 1993;342:767-772.
18. LATE Study Group. Late Assessment of Thrombolytic Efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet 1993;342:759-766.
19. Langer A, Goodman SG, Topol EJ, et al. Late assessment of thrombolytic efficacy (LATE) study: Prognosis in patient with non-Q wave myocardial infarction. JACC 1996;27: 1327-1332.
20. DeWood MA, Stifter WF, Simpson CS, et al. Coronary arteriographic findings soon after non-Q wave myocardial infarction. N Engl J Med 1986;315:417-423.
21. The TIMI IIIA Investigators. Early effects of tissue-type plasminogen activator added to conventional therapy on the culprit lesion in patients presenting with ischemic cardiac pain at rest: Results of the Thrombolysis in Myocardial Ischemia (TIMI IIIA) trial. Circulation 1993;87:38-52.
22. Granger CB, Califf RM, Topol EJ. Thrombolytic therapy for acute myocardial infarction. A review. Drugs 1992;44: 293-325.
23. Lenderink T, Simoon ML, Van Es G-A, et al. Benefit of thrombolytic therapy is unstained throughout five years and is related to TIMI perfusion grade 3 but not grade 2 flow at dis-charge. Circulation 1995;92:1110-1116.
24. Ross AM, Coyne KS, Moreyra E, et al. Extended mortality benefit of early postinfarction reperfusion. Circulation 1998;97:1549-1556.
25. Cragg DR, Friedman HZ, Bonema JD. et al. Outcome of patients excluded from thrombolytic therapy. Ann Intern Med 1991;115:173-177.
26. Karnash SL, Granger CB, White HD, et al. Treating menstruating women with thrombolytic therapy: Insights from the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-1) Trial. JACC 1995;26:1651-1656.
27. Neches RB, Goldfarb AM. Thrombolytic therapy after cardiopulmonary resuscitation in acute myocardial infarction. Am J Cardiol 1993;71:258.
28. French JK, Williams BF, Hart HH, et al. Prospective evaluation of eligibility for thrombolytic therapy in acute myocardial infarction. Br Med J 1996;312:1637-1641.
29. White HD, Barbash GI, Califf RM, et al. Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I Trial. Circulation 1996;94:1826-1833.
30. Anderson JL. Why does thrombolysis fail? Breaking through the reperfusion ceiling. Am J Cardiol 1997;80:1588-1590.
31. Ross AM. New thrombolytic agents. J Interven Cardiol 1997;10:395-399.
32. Antman EM. TIMI 14: Abciximab plus thrombolytic therapy. Presented at the George Washington University 13th International Workshop: Thrombolysis and Interventional Therapy in Acute Myocardial Infarction. Orlando, FL, November 1997.
33. Ohman EM. GUSTO-IV pilot. Presented at the Myocardial Reperfusion XI: Concepts and Controversies (Cleveland Clinic Foundation). Atlanta, GA, March 1998.
34. Smalling RW, Bode C, Kalbfleisch J, et al. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. Circulation 1995;91:2725-2732.
35. International Joint Efficacy Comparison of Thrombolytics. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): Trial to investigate equivalence. Lancet 1995;346:329-336.
36. Bode C, Smalling RW, Berg G, et al. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation 1996;94:891-898.
37. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997;337:1118-1123.
38. Larsen GR, Timony GA, Morgan PG, et al. Protein engineering of novel plasminogen activators with increased thrombolytic potency in rabbits relative to activase. J Biol Chem 1991;266:8156-8161.
39. Chew P. Presented at the 1996 AHA National Meeting. Personal communication.
40. Benedict CR, Refino CJ, Keyt BA, et al. New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA. Circulation 1995:92:3032-3040.
41. Cannon CP, McCabe CH, Gibson M, et al. TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A Dose-Ranging trial. Circulation 1997;95:351-356.
42. Cannon CP, McCabe CH. TNK-tissue plasminogen activator compared with front-loaded tissue plasminogen activator in acute myocardial infarction: Primary results of the TIMI 10B trial, (abstract) Circulation 1997;96(Suppl I):I-206.
43. White HD, Van de Werf FJJ. Thrombolysis for acute myocardial infarction. Circulation 1998;97:1632-1646.
44. Collen D, De Cock F, Demarsin E, et al. Recombinant staphylokinase variants with altered immunoreactivity. III: Species variability of antibody binding patterns. Circulation 1997:95:455-462.
45. Collen D, Stockx L, Lacroix H, et al. Recombinant staphylokinase variants with altered immunoreactivity. IV: Identification of variants with reduced antibody induction but intact potency. Circulation 1997;95:463-472.
46. Vanderschueren S, Barrios L, Kerdsinchai P, et al. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. Circulation 1995;92:2044-2049.
47. Vanderschueren S, Dens J, Kerdsinchai P, et al. Randomized coronary patency trial of double-bolus recombinant staphylokinase versus front-loaded alteplase in acute myocardial infarction. Am Heart J 1997;134:213-219.
48. Vanderschueren S, Stockx L, Wilms G, et al. Thrombolytic therapy of peripheral arterial occlusion with recombinant staphylokinase. Circulation 1995;92:2050-2057.
49. Tebbe U, Michels R, Adgey J, et al. Randomized, double-blind study comparing saruplase with streptokinase therapy in acute myocardial infarction: The COMPASS Equivalence Trial. JACC 1998;31:487-493.
50. Kawai C, Yui Y, Hosoda S, et al. A prospective, randomized, double-blind multicenter trial of a single bolus injection of the novel modified t-PA E6010 in the treatment of acute myocardial infarction: Comparison with native t-PA. JACC 1997;29:1477-1453.
51. White HD, Aylward PE, Frey MJ, et al. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Circulation 1997;96:2155-2161.
52. Topol EJ, Califf RM, George BS, et al. A randomized trail of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med 1987;317:581-588.
53. TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial. N Engl J Med 1989;320:618-627.
54. Arnold AER, Serruys PW, Rutsch W, et al. For the European Cooperative Study Group for rtPA. Reasons for no additional benefit of angioplasty immediately after recombinant tissue plasminogen activator for acute myocardial infarction: A regional wall motion analysis. JACC 1991;17:11-21.
55. SWIFT Trial Study Group. SWIFT trial of delayed elective intervention versus conservative treatment after thrombolytic therapy for acute myocardial infarction. Br Med J 1991;302:555-560.
56. O'Neill WW, Weintraub R, Grines CL, et al. A prospective, placebo-controlled, randomized trial of intravenous streptokinase and angioplasty versus lone angioplasty therapy of acute myocardial infarction. Circulation 1992;86:1710-1717.
57. Ross AM. The Plasminogen Activator-Angioplasty Compatibility Trial (PACT). Presented at the George Washington University 13th International Workshop: Thrombolysis and Interventional Therapy in Acute Myocardial Infarction. Orlando, FL, November 1997.
58. O'Neill W, Timmis GC, Bourdillon PD, et al. A prospective randomized clinical trial of intracoronary streptokinase versus coronary angioplasty for acute myocardial infarction. N Engl J Med 1986;314:812-818.
59. Grines CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1993;328:673-679.
60. Parisi AF, Folland ED, Hartigan P. A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. N Engl J Med 1992;326:10-16.
61. Gibbons RJ, Holmes DR, Reeder GS, et al. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. N Engl J Med 1993;328:685-691.
62. Zijlstra F, De Boer MJ, Hoorntje JCA, et al. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med 1993;328:680-684.
63. Zijlstra F, Beukema WP, van't Hof AWJ, et al. Randomized comparison of primary coronary angioplasty with thrombolytic therapy in low risk patients with acute myocardial infarction. JACC 1997;29:908-912.
64. De Boer MJ, Hoorntje JCA, Ottervanger JP, et al. Immediate coronary angioplasty versus intravenous streptokinase in acute myocardial infarction: Left ventricular ejection fraction, hospital mortality and reinfarction. JACC 1994;23:1004-1008.
65. Every NR, Parsons LS, Hlatky M, et al. A comparison of thrombolytic therapy with primary coronary angioplasty for acute myocardial infarction. N Engl J Med 1996;335: 1253-1260.
66. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1997;336: 1621-1628.
67. Weaver WD, Simes J, Betriu A, et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction. A quantitative review. JAMA 1997;278:2093-2098.
68. Yusuf S. Primary angioplasty compared with thrombolytic therapy for acute myocardial infarction. (Editorial). JAMA 1997;278:2110-2111.